# US 2024/0199696 A1 · Agents for manufacture of co-assembling peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199696 A1
- Document ID: US20240199696A1
- Status: Published application
- Kind: A1
- Application number: 18/287,368
- Filed: 2022-04-19
- Published: 2024-06-20
- Earliest claimed: 2021-04-19
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Incorporated
- Inventors: Gregory Allan Hudalla; Renjie Liu
- Web page: https://patentgrep.com/patent/US20240199696A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- C07K 14/001: {by chemical synthesis}
- C12N 9/0069: {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C12Y 113/12007: Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C12Y: ENZYMES

## Abstract

Provided herein are co-assembling peptides which may form particles (e.g., nanoparticles or granules) under stimulating conditions. Also provided herein are protein carrying particles (e.g., nanoparticles or granules). Further provided herein, are methods of making each of the co-assembling peptides and particles (e.g., nanoparticles or granules).

## Claims

### Claim 1

A composition comprising a plurality of co-assembling peptides and at least one type of crowding agent.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the co-assembling peptides comprise:
(a) at least one positive peptide comprising at least 3 amino acids (A3-A1), wherein A3, A2, and A1 individually represent consecutive amino acid residues in the positive peptide read in the direction N-terminus to C-terminus, wherein A3, A2, and A1 are each independently selected from a positively charged amino acid and a hydrophobic amino acid, and wherein at least one amino acid of A3-A1 is a positively charged amino acid and at least one amino acid of A3-A1 is a hydrophobic amino acid; and
(b) at least one negative peptide comprising at least 3 amino acids (B3-B1), wherein B3, B2, and B1 individually represent consecutive amino acid residues in the negative peptide read in the direction N-terminus to C-terminus, wherein B3, B2, and B1 are each independently selected from a negatively charged amino acid and a hydrophobic amino acid, and wherein at least one amino acid of B3-B1 is a negatively charged amino acid and at least one amino acid of B3-B1 is a hydrophobic amino acid.

### Claim 3 (depends on 1, 2)

The composition of claim 1 or claim 2, wherein the crowding agent is selected from: a composition having a largest cross-sectional length of between 5 nanometer (nm) and 15 nm, and a surfactant.

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1 to 3, wherein the crowding agent is non-ionic.

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1 to 4, wherein the crowding agent is not: ionic, charged, and/or zwitterionic.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The composition of any one of claims 1 to 5, wherein the crowding agent is a polymer comprising a molecular mass of 1000-1,000,000 Da.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1 to 6, wherein the crowding agent is Polysorbate 20 (IUPAC: Polyoxyethylene (20) sorbitan monolaurate; commercially known as “Tween 20”™), polysorbate 80 (IUPAC: Polyoxyethylene (20) sorbitan monooleate; commercially known as “Tween 80”™), (1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol, Polyethylene glycol tert-octylphenyl ether (commercially known as “Triton X-114”™), sodium dodecylsulfate (SDS), deoxycholate sodium, (3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate) (commonly known as CHAPS detergent), benzalkonium chloride, polyethylene glycol 1000 (PEG 1000), PEG 1550, PEG 2000, PEG 3350, PEG 6000, PEG 20000, PEG 50000, Ficoll 70, Ficoll 400, serum albumin, and/or dextran (50 k or 500 k) or any combination thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of any one of claims 1 to 7, wherein at least one cargo is attached to:
(a) at least one positive peptide;
(b) at least one negative peptide; and/or
(c) at least one positive peptide and at least one negative peptide.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the cargo is a therapeutic agent or diagnostic agent.

### Claim 10 (depends on 8, 9)

The composition of claim 8 or claim 9, wherein the cargo is a detectable molecule.

### Claim 11 (depends on 8, 9, 10)

The composition of any one of claims 8 to 9-10, wherein the cargo is a protein, nucleic acid, or small molecule.

### Claim 12 (depends on 8, 9)

The composition of claim 8 or claim 9, wherein the cargo is an enzyme, optionally wherein the enzyme is selected from: indoleamine 2,3-dioxygenase, adenosine synthase A, luciferase, or a combination thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The composition of any one of claims 1 to 12, wherein the co-assembling peptides form a nanoparticle.

### Claim 14

A method of preparing a composition comprising particles of a plurality of co-assembling peptides, the method comprising contacting a plurality of co-assembling peptides with at least one type of crowding agent.

### Claim 15 (depends on 14)

The method of claim 14, wherein the co-assembling peptides comprise:
(a) at least one positive peptide comprising at least 3 amino acids (A3-A1), wherein A3, A2, and A1 individually represent consecutive amino acid residues in the positive peptide read in the direction N-terminus to C-terminus, wherein A3, A2, and A1 are each independently selected from a positively charged amino acid and a hydrophobic amino acid, and wherein at least one amino acid of A3-A1 is a positively charged amino acid and at least one amino acid of A3-A1 is a hydrophobic amino acid; and
(b) at least one negative peptide comprising at least 3 amino acids (B3-B1), wherein B3, B2, and B1 individually represent consecutive amino acid residues in the negative peptide read in the direction N-terminus to C-terminus, wherein B3, B2, and B1 are each independently selected from a negatively charged amino acid and a hydrophobic amino acid, and wherein at least one amino acid of B3-B1 is a negatively charged amino acid and at least one amino acid of B3-B1 is a hydrophobic amino acid.

### Claim 16 (depends on 14, 15)

The method of claim 14 or claim 15, wherein the crowding agent is selected from: a composition having a solid outer shell having a largest cross-sectional length of between 5 nanometer (nm) and 15 nm, and a surfactant.

### Claim 17 (depends on 14, 15, 16)

The method of any one of claims 14 to 16, wherein the crowding agent is non-ionic.

### Claim 18 (depends on 14, 15, 16, 17)

The method of any one of claims 14 to 17, wherein the crowding agent is not: ionic, charged, and/or zwitterionic.

### Claim 19 (depends on 14, 15, 16, 17, 18)

The method of any one of claims 14 to 18, wherein the crowding agent is a polymer comprising a molecular mass of 1000-1,000,000 Da.

### Claim 20 (depends on 14, 15, 16, 17, 18, 19)

The method of any one of claims 14 to 19, wherein the crowding agent is Polysorbate 20 (IUPAC: Polyoxyethylene (20) sorbitan monolaurate; commercially known as “Tween 20”™) polysorbate 80 (IUPAC: Polyoxyethylene (20) sorbitan monooleate; commercially known as “Tween 80”™), (1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol, Polyethylene glycol tert-octylphenyl ether (commercially known as “Triton X-114”™), sodium dodecylsulfate (SDS), deoxycholate sodium, (3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate) (commonly known as CHAPS detergent), benzalkonium chloride, polyethylene glycol 1000 (PEG 1000), PEG 1550, PEG 2000, PEG 3350, PEG 6000, PEG 20000, PEG 50000, Ficoll 70, Ficoll 400, serum albumin, and/or dextran (50 k or 500 k) or any combination thereof.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 14 to 20, wherein at least one cargo is attached to:
(a) at least one positive peptide;
(b) at least one negative peptide; and/or
(c) at least one positive peptide and at least one negative peptide.

### Claim 22 (depends on 21)

The method of claim 21, wherein the cargo is a therapeutic agent or diagnostic agent.

### Claim 23 (depends on 21, 22)

The method of claim 21 or claim 22, wherein the cargo is a detectable molecule.

### Claim 24 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 14 to 23, wherein the concentration of the crowding agent in the solution is:
(a) below the critical concentration required for the assembly of peptides into a fibrillar architecture in the absence of a crowding agent; and/or
(b) wherein the concentration of the surfactant is above the critical concentration required to form micelles/spherical structures.

### Claim 25 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 14 to 24, wherein the concentration of the crowding agent is about 1% to about 50% (e.g., about 10% to about 25%) of the solution (volume to volume (v/v) or wt %).

### Claim 26 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 14 to 25, wherein the at least one positive peptide and the at least one negative peptide do not form a hydrogel.

### Claim 27 (depends on 21, 22, 23, 24, 25, 26)

The method of any one of claims 21 to 26, wherein the cargo is a protein, nucleic acid, or small molecule.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 21 to 27, wherein the cargo is an enzyme, optionally wherein the enzyme is selected from: indoleamine 2,3-dioxygenase, adenosine synthase A, luciferase, or a combination thereof.

### Claim 29 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 14 to 28, wherein the co-assembling peptides form a nanoparticle.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 21 to 29, wherein the at least one cargo is attached to the at least one positive peptide and/or the at least one negative peptide prior to:
(a) introduction to the solution; and/or
(b) assembly of the co-assembling peptides.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 21 to 30, wherein the at least one cargo is attached to the at least one positive peptide and/or the at least one negative peptide after:
(a) introduction to the solution; and/or
(b) assembly of the co-assembling peptides.

### Claim 32 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 19 to 31, wherein the at least one positive peptide and/or at least one negative peptide is a fusion protein with at least one cargo.

### Claim 33

A method of treating a subject, comprising administering the composition of any one of claims to 13 to a subject.

### Claim 34 (depends on 33)

The method of claim 33, wherein the subject is a mammal.

### Claim 35 (depends on 33, 34)

The method of claim 33 or claim 34, wherein the subject is human.

### Claim 36 (depends on 31, 32, 33, 34, 35)

The method of any one of claims 31 to 35, wherein the composition is administered: subcutaneously, intramuscularly, intravenously, intrathecally, intra-articularly, intra-ocularly, sub-gingivally, by inhalation, oral intravascularly, or combination thereof.

### Claim 37 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 21 to 36, wherein the crowding agent is a polymer comprising a molecular mass of 1000-1,000,000 Da.
